A Meal Replacement Program for the Treatment of Obesity: A Cost-Effectiveness Analysis from the Swiss Payer's Perspective.
OPTI program
cost-effectiveness
obesity
total meal replacement
Journal
Diabetes, metabolic syndrome and obesity : targets and therapy
ISSN: 1178-7007
Titre abrégé: Diabetes Metab Syndr Obes
Pays: New Zealand
ID NLM: 101515585
Informations de publication
Date de publication:
2021
2021
Historique:
received:
23
12
2020
accepted:
04
06
2021
entrez:
16
7
2021
pubmed:
17
7
2021
medline:
17
7
2021
Statut:
epublish
Résumé
Obesity is a disease associated with high direct medical costs and high indirect costs resulting from productivity loss. The high prevalence of obesity generates the need for payers to identify cost-effective weight loss approaches. Among various weight management techniques, the OPTI (Optifast An event-driven decision-analytic model was used to estimate the payer's cost savings through the reimbursement of OPTI program over a 1-year period as well as a lifetime in Switzerland. The analysis was performed on a broad population of people with obesity with a body mass index (BMI) higher than 30 kg/m The OPTI program results in cost savings of CHF 20,886 (€ 18,724) and CHF 15,382 (€ 13,790) per person compared with "no intervention" and liraglutide 3 mg, respectively. In addition, OPTI program led to 1.133 and 0.734 quality-adjusted life years (QALYs) gained respectively against its comparators. Scenario analyses showed similar outcomes with cost savings and QALYs gained. OPTI program is a dominant strategy compared to "no intervention" and liraglutide 3 mg as it leads to both cost savings and QALY gain. Therefore, reimbursing the OPTI program for patients with obesity would be cost-effective for Swiss payers.
Sections du résumé
BACKGROUND
BACKGROUND
Obesity is a disease associated with high direct medical costs and high indirect costs resulting from productivity loss. The high prevalence of obesity generates the need for payers to identify cost-effective weight loss approaches. Among various weight management techniques, the OPTI (Optifast
METHODS
METHODS
An event-driven decision-analytic model was used to estimate the payer's cost savings through the reimbursement of OPTI program over a 1-year period as well as a lifetime in Switzerland. The analysis was performed on a broad population of people with obesity with a body mass index (BMI) higher than 30 kg/m
RESULTS
RESULTS
The OPTI program results in cost savings of CHF 20,886 (€ 18,724) and CHF 15,382 (€ 13,790) per person compared with "no intervention" and liraglutide 3 mg, respectively. In addition, OPTI program led to 1.133 and 0.734 quality-adjusted life years (QALYs) gained respectively against its comparators. Scenario analyses showed similar outcomes with cost savings and QALYs gained.
CONCLUSION
CONCLUSIONS
OPTI program is a dominant strategy compared to "no intervention" and liraglutide 3 mg as it leads to both cost savings and QALY gain. Therefore, reimbursing the OPTI program for patients with obesity would be cost-effective for Swiss payers.
Identifiants
pubmed: 34267531
doi: 10.2147/DMSO.S284855
pii: 284855
pmc: PMC8275158
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3147-3160Informations de copyright
© 2021 Nuijten et al.
Déclaration de conflit d'intérêts
The brand OPTI belongs to Nestlé. LD, KAT, MP and AM are Nestlé employees. All data analyzed in the study come from published literature and publicly disclosed clinical trial results. Nestlé founded the data elaboration and writing the manuscript. The authors report no other conflicts of interest in this work.
Références
Int J Obes (Lond). 2012 Apr;36(4):614-24
pubmed: 21673653
Am J Clin Nutr. 1977 Jan;30(1):16-20
pubmed: 831435
Swiss Med Wkly. 2007 Oct 6;137(39-40):545-50
pubmed: 17990145
PLoS One. 2017 Dec 22;12(12):e0189631
pubmed: 29272281
Eur J Public Health. 2015 Apr;25(2):255-62
pubmed: 25320051
J Med Econ. 2018 Sep;21(9):835-844
pubmed: 29678127
Can Pharm J (Ott). 2017 Mar 21;150(3):184-197
pubmed: 28507654
Swiss Med Wkly. 2010 Oct 25;140:w13103
pubmed: 21110238
Clin Cancer Res. 2011 Oct 1;17(19):6338-46
pubmed: 21807639
Swiss Med Wkly. 2009 Mar 21;139(11-12):173-84
pubmed: 19330561
CMAJ. 2007 Apr 10;176(8):S1-13
pubmed: 17420481
Diabetes Metab Syndr Obes. 2014 Oct 01;7:455-65
pubmed: 25336981
BMJ Open. 2017 Aug 01;7(7):e015645
pubmed: 28765126
Am J Clin Nutr. 1992 Jul;56(1 Suppl):271S-274S
pubmed: 1615899
Arch Intern Med. 1992 May;152(5):961-6
pubmed: 1580722
J Diabetes Sci Technol. 2015 Aug 14;10(2):366-77
pubmed: 26275642
Br J Haematol. 2013 Jul;162(1):25-39
pubmed: 23647436
Int J Obes (Lond). 2013 Nov;37(11):1443-51
pubmed: 23812094
Diabetes Care. 2010 Sep;33(9):1933-9
pubmed: 20805271
Soz Praventivmed. 2005;50(2):87-94
pubmed: 15900961
Maturitas. 2011 Jul;69(3):220-9
pubmed: 21592692
Obes Rev. 2019 Apr;20(4):569-587
pubmed: 30675990
N Engl J Med. 2015 Jul 2;373(1):11-22
pubmed: 26132939
Pharmacoeconomics. 2015 Feb;33(2):179-90
pubmed: 25404424
Radiother Oncol. 2018 Nov;129(2):257-263
pubmed: 30104008
BMC Public Health. 2009 Mar 25;9:88
pubmed: 19320986
Int J Obes Relat Metab Disord. 2003 Oct;27(10):1167-77
pubmed: 14513064
Value Health. 2015 Sep;18(6):767-73
pubmed: 26409603
J Comp Eff Res. 2017 Jul;6(5):425-436
pubmed: 28541099
J Obstet Gynaecol Can. 2007 Feb;29(2):131-139
pubmed: 17346483
Pharmacoeconomics. 2002;20(6):393-404
pubmed: 12052098
Health Technol Assess. 2002;6(12):1-153
pubmed: 12196283
BMJ. 1997 Oct 11;315(7113):912-6
pubmed: 9361540
Int J Eat Disord. 1997 Sep;22(2):203-12
pubmed: 9261660
Health Technol Assess. 2009 Sep;13(41):1-190, 215-357, iii-iv
pubmed: 19726018
Value Health. 2013 Jun;16(4):498-506
pubmed: 23796283
Obes Res. 2001 Mar;9(3):188-95
pubmed: 11323444
Int J Obes. 1988;12(4):277-84
pubmed: 3058614
J Occup Environ Med. 2010 Oct;52(10):971-6
pubmed: 20881629
Lancet. 2014 Aug 30;384(9945):766-81
pubmed: 24880830
Value Health. 2010 Jan-Feb;13(1):55-60
pubmed: 19804431
Int J Public Health. 2007;52(6):372-82
pubmed: 18369000
Clinicoecon Outcomes Res. 2014 Jan 24;6:49-62
pubmed: 24493930
BMC Res Notes. 2014 Apr 16;7:242
pubmed: 24739239
Int J Obes Relat Metab Disord. 2001 May;25 Suppl 1:S2-4
pubmed: 11466577
N Engl J Med. 1984 Feb 9;310(6):352-6
pubmed: 6690963
BMC Health Serv Res. 2014 Apr 10;14:163
pubmed: 24721557
J Clin Endocrinol Metab. 2015 Feb;100(2):342-62
pubmed: 25590212
Best Pract Res Clin Endocrinol Metab. 2013 Apr;27(2):105-15
pubmed: 23731873
Can J Cardiol. 2015 Feb;31(2):142-52
pubmed: 25661549
PLoS One. 2015 May 14;10(5):e0126984
pubmed: 25974722
BMJ Open. 2016 Jan 12;6(1):e009949
pubmed: 26758265
Curr Med Res Opin. 2014 Jul;30(7):1267-73
pubmed: 24588550
Health Technol Assess. 2018 Dec;22(70):1-82
pubmed: 30520413
Lancet. 1979 Dec 15;2(8155):1255-8
pubmed: 93179
BMC Psychiatry. 2014 Jan 22;14:16
pubmed: 24450548
Obes Facts. 2015;8(3):166-74
pubmed: 25968960
BMC Obes. 2015 Mar 01;2:11
pubmed: 26217526
Pharmacoeconomics. 2015 Jul;33(7):673-89
pubmed: 25471927
Health Qual Life Outcomes. 2008 Oct 21;6:84
pubmed: 18939982